Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The product of SSX1 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. Additionally we are shipping Synovial Sarcoma, X Breakpoint 1 Proteins (6) and many more products for this protein.
Showing 10 out of 36 products:
Human Polyclonal SSX1 Primary Antibody for WB - ABIN2787447
Törnkvist, Natalishvili, Xie, Girnita, DArcy, Brodin, Axelson, Girnita: Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth. in Biochemical and biophysical research communications 2008
In patients with Colon cancer, the expression of SSX1 gene was associated with a poor prognosis.
Meta-analysis of human synovial sarcoma patient series identified two tumor-gentoype-phenotype correlations that were not modeled by the mice, namely a scarcity of male hosts and biphasic histologic features among SS18 (show SS18 Antibodies)-SSX2 (show SSX2 Antibodies) tumors. Re-analysis of human SS18 (show SS18 Antibodies)-SSX1 and SS18 (show SS18 Antibodies)-SSX2 (show SSX2 Antibodies) tumor transcriptomes demonstrated very few consistent differences, but highlighted increased native SSX2 (show SSX2 Antibodies) expression in SS18 (show SS18 Antibodies)-SSX1 tumors.
Data show that SS18 (show SS18 Antibodies)/SSX (show SSX2 Antibodies) tightly regulates the elevated expression of the key Wnt (show WNT2 Antibodies) target AXIN2 (show AXIN2 Antibodies) in primary synovial sarcoma.
a rare variant of the SS18 (show SS18 Antibodies)-SSX1 fusion transcript, which could not be identified by routine procedures for genetic diagnosis, was detected. In addition, 8 missense mutations of cancer-related genes were confirmed
SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies)-induced Wnt (show WNT2 Antibodies)/beta-catenin (show CTNNB1 Antibodies) signaling appears to be of crucial biological importance in synovial sarcoma tumorigenesis and progression.
The mRNA levels of SSX1 and SSX4 (show SSX4 Antibodies) are associated with multiple myeloma clinical stage
These results suggest that the characteristic speckle localization pattern of SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies) is strongly involved in the tumorigenesis through the SSX (show SSX2 Antibodies) moiety of the SS18 (show SS18 Antibodies)-SSX (show SSX2 Antibodies) fusion protein.
Knockdown of SS18 (show SS18 Antibodies)-SSX1 in synovial sarcoma inhibits viability and induces apoptosis.
Study shows that the SS18 (show SS18 Antibodies)-SSX1 oncogenic fusion usurps SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies)-like BAF (show BANF1 Antibodies) complexes, resulting in activation of Sox2 (show SOX2 Antibodies), which drives proliferation.
siRNA targeting of SS18 (show SS18 Antibodies)-SSX1 has therapeutic potential for the treatment of synovial sarcoma.
The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X\\\\;18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity.
, cancer/testis antigen 5.1
, cancer/testis antigen family 5, member 1
, sarcoma, synovial, X-chromosome-related 1
, synovial sarcoma, X breakpoint 1